APA (7th ed.) Citation

Ø, T., HK, B., EA, H., KB, A., A, B., HØ, F., . . . KM, M. (2026). Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis. The New England journal of medicine, 395(1), 44. https://doi.org/10.1056/NEJMoa2600993

Chicago Style (17th ed.) Citation

Ø, Torkildsen, et al. "Rituximab Versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis." The New England Journal of Medicine 395, no. 1 (2026): 44. https://doi.org/10.1056/NEJMoa2600993.

MLA (9th ed.) Citation

Ø, Torkildsen, et al. "Rituximab Versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis." The New England Journal of Medicine, vol. 395, no. 1, 2026, p. 44, https://doi.org/10.1056/NEJMoa2600993.